Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors-Reference-Cited by-同舟云学术

Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors

Published:2019-09 Issue: Volume:14 Page:126-133
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Kruzik Anita,Fetahagic Damir,Hartlieb Bettina,Dorn Sebastian,Koppensteiner Herwig,Horling Frank M.,Scheiflinger Friedrich,Reipert Birgit M.,de la Rosa Maurus

Funder

Baxalta Innovations GmbH

Baxalta US Inc.

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference30 articles.

1. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue;Duan;J. Virol.,1998

2. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo;Nakai;J. Virol.,2001

3. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy;Gao;Proc. Natl. Acad. Sci. USA,2002

4. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response;Manno;Nat. Med.,2006

5. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy;Louis Jeune;Hum. Gene Ther. Methods,2013

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies;Molecular Therapy - Methods & Clinical Development;2024-09

2. Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States;Journal of Managed Care & Specialty Pharmacy;2024-08

3. Essential role of pre-existing humoral immunity in TLR9-mediated type I IFN response to recombinant AAV vectors in human whole blood;Frontiers in Immunology;2024-06-28

4. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States;Journal of Medical Economics;2024-06-06

5. Preexisting maternal immunity to AAV but not Cas9 impairs in utero gene editing in mice;Journal of Clinical Investigation;2024-05-09